Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Astellas Aims to Dominate SGLT-2 Inhibitor Market with Suglat
April 23, 2014
- Lilly Japan Starts PIII Study of Tadalafil for DMD Treatment
April 22, 2014
- Metal Objects Found in Voltaren Suppositories in Aichi Pref.: Novartis
April 22, 2014
- Nihon Generic Obtains Teva’s Manufacturing Plant, Eyeing Expansion of Production Capacity
April 22, 2014
- Entry into Japan Biosimilar Market Will Take Time, Says BI Chairman
April 21, 2014
- PIII Trial of Asthma Drug Benralizumab Kicks Off in Japan: Kyowa Kirin
April 21, 2014
- NBI Postpones Launch of Anticancer Drug Giotrif until May 7
April 21, 2014
- Kyowa Kirin, Amgen of US Terminate License Agreement for Mogamulizumab
April 21, 2014
- Astellas Launches Japan’s 1st SGLT-2 Inhibitor Suglat
April 18, 2014
- Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
April 18, 2014
- “MRs’ Manners” Are Opening Theme in Panel Discussion Held by MREAC
April 18, 2014
- Sales of Diovan Fell 22% in 3rd Quarter of FY2013; Overall Growth of ARB Market Could Fall Short of Expectations
April 18, 2014
- Boehringer Ingelheim Reports 14.1% Increase in Operating Profit to 2,114 Million Euro in 2013
April 17, 2014
- Metal Found in Voltaren Product Again: Novartis
April 17, 2014
- AZ Offers Sales Rep Jobs to over 100 New Graduates in FY2014
April 16, 2014
- Eisai President Naito Awarded Honorary KBE
April 16, 2014
- FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
April 15, 2014
- Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
April 15, 2014
- Hisamitsu Total Sales Up 5.5% but Domestic Ethical Drug Sales Down 1.8%
April 14, 2014
- Patient Enrollment for PI Trial of Anticancer Drug HF10 in US Completed, Takara Bio
April 14, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…